Literature DB >> 23178978

The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma.

Momar Diouf1, Thomas Filleron, Jean-Claude Barbare, Loïc Fin, Carl Picard, Olivier Bouché, Laetitia Dahan, Xavier Paoletti, Franck Bonnetain.   

Abstract

BACKGROUND & AIMS: Several prognostic classifications (PCs) have been developed for use in palliative care in patients with hepatocellular carcinoma (HCC). We have recently suggested that CLIP combined with WHO PS has the greatest discriminative power. We evaluated the prognostic value of quality of life (QoL) data and whether the latter could improve classification of palliative HCC patients.
METHODS: This was a reanalysis from the CHOC trial with an evaluation of the discriminative power for overall survival (OS) of the established CLIP/GRETCH/BCLC/BoBar prognostic systems alone and then in association with each of the following groups of parameters: selected clinical factors, QoL as continuous variables, dichotomized QoL, selected clinical factors and continuous QoL, selected clinical factors and dichotomized QoL. Baseline QoL was assessed using the EORTC QLQ-C30. Discriminative power was evaluated with the Harrell's C-index and net reclassification improvement.
RESULTS: Quality of life was available in 79% of the patients (n=271). Univariate analysis revealed that better role functioning (HR=0.991 [0.987-0.995]) and better physical functioning (0.991 [0.984-0.997]) scores were associated with longer survival. In contrast, poorer score for fatigue (1.011 [1.006-1.015]) and diarrhoea (1.008 [1.002-1.013]) were associated with shorter survival. After adjustment for clinical and sociodemographic variables, only better role functioning score (0.993 [0.988-0.998]) was associated with longer survival. Adding oedema, hepatomegaly, fatigue and diarrhoea QoL scales to CLIP resulted in the best performance.
CONCLUSIONS: Our results confirm that QoL scales are independent prognostic factors of OS in palliative HCC patients. Incorporation of QoL data improved all the studied PCs.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23178978     DOI: 10.1016/j.jhep.2012.11.019

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  26 in total

Review 1.  Management of hepatocellular carcinoma.

Authors:  P Fitzmorris; M Shoreibah; B S Anand; A K Singal
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-27       Impact factor: 4.553

Review 2.  Staging systems for hepatocellular carcinoma: Current status and future perspectives.

Authors:  Akiyoshi Kinoshita; Hiroshi Onoda; Nao Fushiya; Kazuhiko Koike; Hirokazu Nishino; Hisao Tajiri
Journal:  World J Hepatol       Date:  2015-03-27

3.  Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma.

Authors:  Momar Diouf; Franck Bonnetain; Jean-Claude Barbare; Olivier Bouché; Laetitia Dahan; Xavier Paoletti; Thomas Filleron
Journal:  Oncologist       Date:  2014-12-26

4.  Role functioning is associated with survival in patients with hepatocellular carcinoma.

Authors:  Adam Meier; Adam Yopp; Huram Mok; Pragathi Kandunoori; Jasmin Tiro; Amit G Singal
Journal:  Qual Life Res       Date:  2014-12-13       Impact factor: 4.147

Review 5.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Robin Kate Kelley; Augusto Villanueva; Amit G Singal; Eli Pikarsky; Sasan Roayaie; Riccardo Lencioni; Kazuhiko Koike; Jessica Zucman-Rossi; Richard S Finn
Journal:  Nat Rev Dis Primers       Date:  2021-01-21       Impact factor: 52.329

Review 6.  A closer look at quality of life in the hepatocellular carcinoma literature.

Authors:  Jenny L Firkins; Robin Tarter; Martha Driessnack; Lissi Hansen
Journal:  Qual Life Res       Date:  2021-02-24       Impact factor: 4.147

7.  Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology.

Authors:  Momar Diouf; Thomas Filleron; Anne-Laure Pointet; Anne-Claire Dupont-Gossard; David Malka; Pascal Artru; Mélanie Gauthier; Thierry Lecomte; Thomas Aparicio; Anne Thirot-Bidault; Céline Lobry; Francine Fein; Olivier Dubreuil; Bruno Landi; Aziz Zaanan; Julien Taieb; Franck Bonnetain
Journal:  Qual Life Res       Date:  2015-11-28       Impact factor: 4.147

Review 8.  Quality of life and hepatocellular carcinoma.

Authors:  Shipra Gandhi; Sapna Khubchandani; Renuka Iyer
Journal:  J Gastrointest Oncol       Date:  2014-08

9.  Left Ventricular Diastolic Dysfunction is Associated with Renal Dysfunction, Poor Survival and Low Health Related Quality of Life in Cirrhosis.

Authors:  Madhumita Premkumar; Devaraja Devurgowda; Tanmay Vyas; Saggere M Shasthry; Jelen S Khumuckham; Ritu Goyal; Sherin S Thomas; Guresh Kumar
Journal:  J Clin Exp Hepatol       Date:  2018-08-30

10.  Effects of Home Care on patients with hepatocellular carcinoma treated with sorafenib.

Authors:  Monika Moser; Iuliana-Pompilia Radu; Jean-François Dufour
Journal:  JGH Open       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.